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Abstract
Background: In 2009 a new influenza serotype (AH1N1) was identified in Mexico that spread rapidly generating
worldwide alarm. San Luis Potosi (SLP) was the third state with more cases reported in that year. The clinical
identification of this flu posed a challenge to medical staff. This study aimed at estimating the AH1N1 infection,
hospitalization and mortality rates, and at identifying related clinical features in persons who received medical care
during the influenza pandemic.
Methods: Retrospective study with persons with flu-like illness who received public or private medical care in SLP from
15.03.09 to 30.10.09. Physicians purposely recorded many clinical variables. Samples from pharyngeal exudate or
bronchoalveolar lavage were taken to diagnose AH1N1 using real-time PCR. Clinical predictors were identified using
multivariate logistic regression with infection as a dependent variable. Odds ratios (OR) with 95% confidence intervals
(CI) were computed. Analyses were stratified by age group based on the distribution of positive cases.
Results: From the 6922 persons with flu symptoms 6158 had available laboratory results from which 44.9% turned out
to be positive for AH1N1. From those, 5.8% were hospitalized and 0.7% died. Most positive cases were aged
5–14 years and, in this subgroup, older age was positively associated with A H1N1 infection (95% CI 1.05-1.1);
conversely, in patients aged 15 years or more, older age was negatively associated with the infection (95% CI 0.97-0.98).
Fever was related in those aged 15 years or more (95% CI 1.4-3.5), and headache (95% CI 1.2-2.2) only in the 0–14 years
group. Clear rhinorrhea and cough were positively related in both groups (p < 0.05). Arthralgia, dyspnea and
vaccination history were related to lesser risk in persons aged 15 years or more, just as dyspnea, purulent rhinorrhea
and leukocytosis were in the 0–14 years group.
Conclusion: This study identified various signs and symptoms for the clinical diagnosis of AH1N1 influenza and
revealed that some of them can be age-specific.
Background
Influenza A virus is a main cause of winter epidemics that
results in increments in respiratory morbidity. It constitu-
tes a public health concern due to the burden that it
represents for the health system and labor market, and for
its potential to evolve into a pandemic [1-3]. The virus is
sub-classified based on its surface glycoproteins, hemaglu-
tinin and neuroaminidase, which confer the pathogenicity
[1,3-6]. Its high antigenic mutation capability is respon-
sible for the cyclic outbreaks observed annually [1,5].
Transmission is mainly person to person through aero-
sol particles expelled by ill individuals when coughing or
sneezing, but also through contact with hands or contami-
nated fomites [5]. The incubation period ranges from
hours to days [5], with an average of two days [6].
Although some patients might be asymptomatic, most
present signs and symptoms of varying severity after a few
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days of contracting the disease [6,7], but the majority usu-
ally recover within one or two weeks [1].
The first flu pandemic was recorded in 1538 [5]. In the
last century three pandemics reached the equivalent of
Category 2 on the CDC pandemic severity index (case-fa-
tality ratio >0.1%), and all were attributed to the subtype A
[1]: The Spanish flu (AH1N1) from 1918–1920 dissemi-
nated in Europe and the US causing about 50 million
deaths [3,5,6,8]; the Asian flu (AH2N2) from 1957–1958,
responsible for 1–4 million deaths, was caused by a viral
mutation that resulted in a combination of avian and
human strains; and the Hong Kong flu (AH3N2) from
1968–1969 that resulted from an antigenic shift caused
nearly 1 million deaths [5,8].
The last pandemic started in Mexico in March 2009,
when the Ministry of Health recognized an unexpected
outbreak of respiratory disease [9] that would later be
identified as AH1N1, a new viral strain resulting from a
genetic combination of bird, pig and human influenza
viruses [10]. The mutation detected in the nuclear M
protein, responsible for the resistance to amantadine com-
pounds, similar to that found in the AH5N1 Hong Kong
virus from 1997, caused concern due to the high lethality
seen with this kind of strain, and because of the high
infectivity of this new virus [8].
By May, many countries started reporting cases, and as
a result WHO defined the event of international import-
ance [9], and governments implemented an emergency
response plan to limit the viral spread and consequences
[11]. In Mexico, educational and other non-essential activ-
ities were suspended for weeks to prevent people from
getting infected [12]. By June 11, the WHO officially
declared a pandemic [13].
Fortunately, this pandemic was less lethal than expected,
resulting in about 18 500 deaths worldwide in 2009 [13].
In Mexico around 73 000 cases with nearly 1 350 deaths
were confirmed, resulting in a lethality rate of ~1.8%
[14,15]. San Luis Potosi (SLP) state, where this study was
conducted, accounted for 6.1% of the cases registered in
the country, in spite of having only 2% of the Mexican
population (2.5 million) [14]. It was in fact the state with
the third most cases reported [15].
The limited knowledge about the symptomatology
associated with the presence of AH1N1 made it very
difficult for physicians to clinically distinguish this flu
virus from other respiratory infections. A better under-
standing of the association between symptomatology
and the presence of the virus could assist in future diag-
nostic efforts.
This study estimated the AH1N1 infection, hospital-
ization and mortality rates in SLP during the 2009 pan-
demic, and aimed at identifying clinical features associated
with AH1N1 infection in individuals with flu-like illness
who sought medical care.
Methods
Study design
This study retrospectively investigated data gathered on
patients suspected to be infected by AH1N1 virus during
the 2009 outbreak and for which a set of clinical data was
systematically collected.
Individuals of all ages with flu symptomatology who
sought medical attention from 15.03.09 to 30.10.09 at any
of the nearly 500 public or private health care facilities that
integrated the Epidemiological Surveillance System for
Influenza (ESSI) in the central Mexican state of SLP
[16,17] were eligible for these analyses.
A working clinical definition was set during the pan-
demic to screen for all persons presenting fever, cough
and headache [18,19], who were considered potentially
infected, and respiratory tract samples were obtained to
confirm the diagnosis; for infants irritability was used
instead of headache, and in the elderly population fever
could be missing [13,19]. In addition to these symptoms,
many other clinical variables were systematically measured
and recorded. In some cases, physicians decided to include
patients for laboratory screening in spite of not having the
pre-required three clinical manifestations.
Data source
Data was extracted from the ESSI, administered by SLP
State Health Services [16]. When a patient fulfilled the
criteria for a probable case, physicians had to complete a
specific questionnaire that included information about the
patient’s basic socio-demographic characteristics, the unit
where the health care was provided, the complete clinical
symptomatology, the use of previous treatment, and data
on specific epidemiological risk factors. These formats
were then sent to one of the six health jurisdictions of SLP
where data were coded and manually entered into the
ESSI.
Samples from pharyngeal or nasopharyngeal exudate, or
bronchoalveolar lavage were taken from all patients who
fulfilled the operational definition to confirm the diagnosis
of AH1N1 using real-time polymerase chain reaction
(RT-PCR), which has been reported to have a very high
sensitivity and specificity [20].
Specimens were placed in normal saline solution or viral
transport media, and were kept cooled at 2-4°C [21] before
analyses were carried out at the Public Health Laboratory
of SLP and confirmed by the National Institute for
Diagnostic and Epidemiological Reference in Mexico City,
based on the primers designed by the CDC to detect the
AH1N1 virus [22].
This study was carried out in compliance with the
Helsinki Declaration. Potential ethical concerns derived
from the use of human data were carefully considered;
informed consent was not obtained as data was collected
routinely for epidemiologic surveillance purposes. The
Castillo-Palencia et al. BMC Infectious Diseases 2012, 12:363 Page 2 of 9
http://www.biomedcentral.com/1471-2334/12/363
proposal was reviewed and approved by the Ethics and
Research Committee of SLP State Health Services (regis-
tration number SLP/070-2012) and authorization to use
the data was provided by SLP State Health Services
(approval reference number 19089).
Data selection
For the purpose of this study, the clinical data extracted
from the ESSI registry were recoded when necessary
(e.g. tachypnea from respiratory rate) and classified into
signs (i.e. objective medical characteristic that can be
detected), symptoms (i.e. subjective feature noticed by the
patient that cannot be directly observed), and epidemio-
logical risk factors related to flu infection. Except for few
continuous variables (e.g. age, fever or respiratory rate),
most of these variables were coded dichotomously in the
original questionnaire.
Variables were selected for the analyses if they were
related to respiratory tract infections. However, some had
to be excluded as they contained similar information
(e.g. pharyngitis and sore throat) or because they were con-
sidered irrelevant for this study (e.g. contact with animals
and recent travel). Complete data was available for all the
clinical variables included.
The signs included were fever (arm temperature ≥38°C),
cough, clear or purulent rhinorrhea, nasal congestion, sore
throat, conjunctivitis, dysphonia, tachypnea (≥20 breaths/
min; ≥40 for infants aged ≤5 years), cyanosis and
leukocytosis (≥12000/μL); the symptoms included head-
ache, malaise, chills, myalgia, irritability, arthralgia, thoracic
pain and dyspnea; and the epidemiological risk factors
included recent contact with persons with flu and history
of antiviral treatment within two weeks prior to the inter-
view, immunization against seasonal influenza, current
smoking, and history of diagnosed asthma and chronic
obstructive pulmonary disease.
Statistical analyses
Infection, hospitalization and mortality rates were esti-
mated per 100 individuals and defined as: Infection rate
= Infected cases confirmed by laboratory / Total number
of persons tested with available laboratory result;
Hospitalization rate = Hospitalized with confirmed la-
boratory result / Total number of infected persons; and
Mortality rate = Deaths with confirmed laboratory result
/ Total number of infected persons.
The proportion of persons with positive and negative
AH1N1 infection was plotted by five-year age groups and
compared with the distribution of the state population to
identify the age categories with the highest incidence.
Individuals with positive and negative infection con-
firmed by laboratory were compared using crude odds
ratios (OR) with 95% confidence intervals (CI) for every
clinical feature under study.
Clinical predictors were identified using backward step-
wise logistic regression with infection confirmed by
laboratory as a dependent variable, and all clinical data as
independent variables. Adjusted regression models were
produced for the two age group categories defined: 0–14
years (children), and ≥15 years. All signs, symptoms, and
epidemiological risk factors that showed significant crude
ORs in the bivariate analyses were entered into the initial
models. Cases with missing laboratory data were excluded
from the multivariate analyses (n = 794). Only variables
with significant adjusted ORs, as judged by the 95% CI,
remained in the final models.
The accuracy of the model was evaluated by subtracting
the proportional by chance accuracy rate (PCHAR) to the
overall percentage of accurate predictions seen in the clas-
sification matrix of the final model. The accuracy was con-
sidered acceptable if a ≥25% increase was observed over
the PCHAR. The model fit was assessed using the
Hosmer-Lemeshow goodness-of-fit statistic. A good
model fit was indicated by a non-significant Chi-square
value (p > 0.05). All data was analyzed with IBMW SPSSW
version 18 (IBM, New York, USA).
Results
Table 1 presents the infection, hospitalization and mortal-
ity rates for AH1N1 in SLP compared with geographic
regions of North America with documented statistics of
the like [23-25]. Laboratory results were available for
89.9% of the 6922 persons screened who fulfilled the def-
inition for probable case. Positive results lead to an infec-
tion rate of 44.9%. The hospitalization rate was markedly
higher than the national rate (5.8 vs. 1.5%), but consider-
ably lower than the American and Canadian figures
(~14-15%). The mortality rate (0.7%) was very similar to
the national and Canadian estimates (0.6 and 0.8, respect-
ively), but notably lower than that reported in other
geographic regions. Except for the mortality rates between
Canada, Mexico and SLP, all other rates presented were
statistically different (p < 0.01).
Figure 1 plots the percent distribution of confirmed
cases by age group. From the 2767 patients with AH1N1
infection, 1409 (50.9%) were aged 0–14 years (731 males,
51.9%; 678 females, 48.1%), and 1358 (49.1%) were ≥15
years old (598 males, 44%; 760 females, 56%). There was a
clear overrepresentation of positive cases (dark line)
among children compared with the state population distri-
bution (grey line). Consequently, the proportion of cases
was lower in the adult groups compared with the popula-
tion distribution, including the elderly.
Table 2 presents bivariate analyses for clinical manifesta-
tions associated with AH1N1 infection. Based on the crude
associations (crude OR, 95% CI), most clinical signs and
Castillo-Palencia et al. BMC Infectious Diseases 2012, 12:363 Page 3 of 9
http://www.biomedcentral.com/1471-2334/12/363
symptoms studied were significantly associated: The stron-
gest positive associations with the infection were observed
for fever (4.1, 3.3-5.1), cough (3.3, 2.7-4.0), headache (3.2,
2.6-3.8), and clear rhinorrhea (1.8, 1.6-2.1); and the stron-
gest negative ones, with leukocytosis (0.13, 0.04-0.42),
purulent rhinorrhea (0.56, 0.41-0.77) and dyspnea (0.57,
0.48-0.68). Sex was not related to infection (1.0, 0.9-1.1).
Except for contact with other persons with flu (1.4, 1.2-
1.7), all other epidemiological risk factors considered were
not statistically associated.
Table 3 presents the final logistic regression models by
age group. For children, the model included six variables
with statistically significant positive adjusted ORs (age in
years 1.07, cough 1.5, headache 1.6, clear rhinorrhea 1.3,
contact with flu person 1.6, and conjunctivitis 1.2), and
three with negative adjusted ORs (dyspnea 0.51, purulent
Table 1 AH1N1 influenza infection, hospitalization and mortality rates for individuals with flu symptoms who sought
medical care by geographic area from March to October, 2009




Rate x 100 (n)
Infection3 Hospitalization4 Mortality5
In the World+ - - (482 300) - 1.2 (6 071)
American continent+ - - (185 067) - 2.3 (4 399)
North America
Canada† - - (10 156) 15.7 (1 604) 0.8 (83)
USA† - 134 899 42.7 (57 602) 14.2 (8 204) 1.9 (1 123)
Mexico‡ - - (50 234) 1.5 (800) 0.6 (328)
San Luis Potosi 6 922 6 158 44.9 (2 767) 5.8 (161) 0.7 (21)
1 Fever, headache and cough were compulsory (in infants irritability replaced headache; in elderly fever could be missing), but other symptoms could be present.
2 Nasopharyngeal exudate or bronchoalveolar lavage samples were taken at the moment of the physical exam; RT-PCR was used for diagnosis.
3 Infected cases confirmed by laboratory / total number of persons tested with available laboratory result.
4 Hospitalized with confirmed laboratory result / total number of persons infected.
5 Deaths with confirmed laboratory result / total number of persons infected.
+ Information up to November 1, 2009 [25].
† Information up to October 31, 2009 [23].
‡ Information up to October 26, 2009 [24].
Figure 1 Distribution of individuals by age group with confirmed AH1N1 diagnosis who received medical care for flu symptoms from
March to October 2009 compared with the population distribution of San Luis Potosi State, Mexico.
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rhinorrhea 0.47, and leukocytosis 0.07). The model fitted
well (p 0.11), and the accuracy was 25% more than the
PCHAR (0.62 vs. 0.50). For those aged 15 years or more,
three variables showed statistically significant positive
adjusted ORs (fever 2.2, cough 1.7, and clear rhinorrhea
1.5), and four had negative adjusted ORs (age in years 0.98,
arthralgia 0.81, dyspnea 0.73, and seasonal flu vaccine 0.73).
The accuracy of the model was 24% more than the PCHAR
(0.63 vs. 0.52), and the model also fitted well (p 0.72).
Discussion
An objective of this study was to estimate the AH1N1 in-
fection, hospitalization and mortality rates in this represen-
tative population sample. We observed that 62.7% of the
AH1N1 positive cases occurred in persons aged 0–18 years,
which was very similar to the 60% reported from April 15
to May 5, 2009 in the US [10], and to the 61.8% national
Mexican figure registered from March 11 to May 27, 2009
in those aged 0–19 years [2] (64.2% in this study). Based on
a longer observation period, our study reinforces the
observation that the AH1H1 virus affected mostly infant
and adolescent populations.
The high infection rate seen indicated a rapid transmis-
sion of this virus, since nearly one out of two persons pre-
senting respiratory symptoms such as fever, headache and
cough had a confirmed laboratory diagnosis, and this
supports the value of the operational definition used to
screen individuals.
The hospitalization rate is more problematic to interpret
and compare, as no data regarding the criteria used for
hospitalization was available. While different viral patho-
genicity and/or clinical severity cannot be completely
ruled out, it seems that hospitalization criteria varied con-
siderably across geographic areas, as indicated by the rela-
tively large variation observed (5.8% in SLP, 1.5% in
Mexico, and 14-15% in the US and Canada) [23].
The infection, hospitalization, and mortality rates can be
compared with those of seasonal influenza in SLP during
the same period, which were 5.3% (0-14y 3.7%, ≥15y
4.8%), 9.6% (0-14y 4.9%, ≥15y 12.5%), and 1.8% (0-14y
Table 2 Clinical manifestations associated with AH1N1 influenza infection in individuals who received medical care in
San Luis Potosi State from March to October 2009
Clinical characteristics Confirmed AH1N1 infection, n (%) Crude OR
[95% CI]Positive (n = 2767) Negative (n = 3391)
Signs Fever 2665 (96.3) 2927 (86.3) 4.14 [3.32–5.16]
Cough 2610 (94.3) 2825 (83.3) 3.33 [2.76–4.00]
Clear rhinorrhea 2071 (74.8) 2077 (61.3) 1.88 [1.68–2.10]
Nasal congestion 1376 (49.7) 1361 (40.1) 1.47 [1.33–1.63]
Sore throat 1498 (54.1) 1547 (45.6) 1.40 [1.27–1.55]
Conjunctivitis 728 (26.3) 702 (20.7) 1.36 [1.21–1.54]
Dysphonia 476 (17.2) 505 (14.9) 1.18 [1.03–1.36]
Tachypnea 107 (3.9) 209 (6.2) 0.61 [0.48–0.77]
Cyanosis 28 (1.0) 57 (1.7) 0.59 [0.37–0.94]
Purulent rhinorrhea 57 (2.1) 122 (3.6) 0.56 [0.41–0.77]
Leukocytosis 3 (0.1) 28 (0.8) 0.13 [0.04–0.42]
Symptoms Headache 2591 (93.6) 2785 (82.1) 3.20 [2.68–3.82]
Malaise 2087 (75.4) 2252 (66.4) 1.55 [1.38–1.76]
Chills 1356 (49.0) 1423 (42.0) 1.32 [1.20–1.47]
Myalgia 1775 (64.1) 1977 (58.3) 1.28 [1.15–1.41]
Irritability 262 (9.5) 267 (7.9) 1.22 [1.02–1.46]
Arthralgia 1570 (56.7) 1785 (52.6) 1.18 [1.06–1.30]
Thoracic pain 449 (16.2) 548 (16.2) 1.00 [0.87–1.15]
Dyspnea 218 (7.9) 439 (12.9) 0.57 [0.48–0.68]
Risk factors Contact with infected (flu) 433 (15.6) 374 (11.0) 1.49 [1.29–1.73]
Antiviral treatment1 47 (1.7) 48 (1.4) 1.20 [0.80–1.80]
Seasonal flu vaccine 258 (9.3) 343 (10.1) 0.91 [0.77–1.08]
Asthma/COPD 36 (1.3) 45 (1.3) 0.98 [0.63–1.52]
Smoking 44 (1.6) 62 (1.8) 0.86 [0.58–1.28]
1 Includes mainly acyclovir, amantadine, ribavirin and rimantadine given within 2 weeks prior to the interview.
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0.9%, ≥15y 2.4%), respectively [26]. While the seasonal in-
fection rate contrasts with the much higher rate seen for
AH1N1 (44.9%), the mortality rate is nearly 2.5 times
higher (1.7 vs. 0.7%), pointing to the high infectivity, but
low lethality of this virus, as previously observed [2,6].
The mortality rate was also similar to that of the
Mexican (0.6%) and Canadian (0.8%) national estimates
[23,24] though clearly lower than the US figure (1.9%). This
difference is also difficult to explain, but it is unlikely to be
due to underreporting in SLP, as health authorities mobi-
lized most resources to track down any potential case of
infection during the pandemic.
This study also looked at the association between clinical
features and the presence of AH1N1 infection in persons
who received medical care during the influenza pandemic
in central Mexico, and the role played by age for the mag-
nitude and direction of the association.
The main findings were that fever was associated, but
only in those aged ≥15 years, while headache only in the
0–14 year group. Clear rhinorrhea and cough were
positively related in both groups. Arthralgia, dyspnea and
vaccination history were related to lesser risk in those aged
≥15 years, as dyspnea, purulent rhinorrhea and leukocytosis
were in children.
The frequency of signs and symptoms found among
infected individuals can be compared with that from other
published studies. Fever, cough and sore throat were
present in 96, 94, and 54%, respectively, compared to 94, 92
and 66% in the American Investigation Team [10]. Accord-
ing to the CDC morbidity and mortality weekly report
(May 6, 2009) the most frequent clinical features reported
in Mexico were fever (98%), cough (94%), rhinorrhea (83%),
and headache (80%) [27]; these proportions were relatively
similar to those found in SLP (96, 94, 75, 93%, respectively).
However, comparisons must be treated with caution, espe-
cially with clinical signs, as diagnostic criteria used by
physicians could have varied across studies. The results of
this study are also in line with previous ones showing that
AH1N1 infection was not sex specific [28-30].
Although several attempts have been made to relate clin-
ical characteristics with the presence of the AH1N1 influ-
enza virus, this study has three major strengths. A first
merit lies in the size of the study population, which com-
prises the largest population-based sample (more than
6000 individuals) reported thus far. A second strength
relates to the inclusion of both hospitalized subjects and
outpatients of all ages. The third strength is related to the
data treatment itself where multivariate regression analyses
were used stratified by age group (0–14 and ≥15 years)
defined based on the cut-off seen for the observed distribu-
tion of individuals with confirmed AH1N1 PCR-diagnosis.
The protective odds for infection found with seasonal
vaccination against influenza in the adult population add
to the controversy on this topic, as previous studies have
reported protection [31-35], no effect [36-40], and even
increased risk of infection [41]. While the potential cross-
reactive protection of seasonal influenza vaccines through
humoral and cell-mediated immune responses [42,43]
needs further investigation, an upcoming review to assess
the protection offered by influenza vaccines against
circulating influenza A or B viruses that are not antigeni-
cally well-matched to vaccine strains will help elucidating
this issue [44].
An additional finding is that clinical manifestations
commonly related to bacterial respiratory infections, such
as purulent rhinorrhea or leukocytosis, were negatively
Table 3 Adjusted logistic regression models with clinical features associated with AH1N1 infection in persons with flu
symptoms who received medical care in San Luis Potosi from March 15 to October 30, 2009, stratified by age group
Variables included in the final model 0-14 years (n = 2698) ≥15 years (n = 3430)
Coefficient Adjusted OR [95% CI] P-value Coefficient Adjusted OR [95% CI] P-value
Age in years 0.07 1.07 [1.05-1.10] 0.000 −0.02 0.98 [0.97-0.98] 0.000
Fever – – – 0.80 2.23 [1.41-3.54] 0.001
Cough 0.46 1.59 [1.12-2.24] 0.009 0.57 1.78 [1.19-2.67] 0-005
Headache 0.50 1.65 [1.21-2.25] 0.001 – – –
Clear rhinorrhea 0.26 1.30 [1.08-1.57] 0.005 0.41 1.50 [1.28-1.77] 0.000
Arthralgia – – – −0.20 0.81 [0.69-0.96] 0.014
Seasonal flu vaccine – – – −0.31 0.73 [0.57-0.93] 0.011
Contact with infected 0.52 1.68 [1.33-2.13] 0.000 – – –
Conjunctivitis 0.25 1.29 [1.07-1.56] 0.007 – – –
Dyspnea −0.65 0.51 [0.35-0.75] 0.001 −0.31 0.73 [0.59-0.90] 0.003
Purulent rhinorrhea −0.75 0.47 [0.28-0.78] 0.004 – – –
Leukocytosis −2.56 0.07 [0.00-0.62] 0.017 – – –
Intercept −1.61 −1.11
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associated with the likelihood of positivity. This finding is
similar to that reported by other authors. In a sample of
362 patients presenting with flu syndrome to an emergency
unit in Spain, nasopharyngeal swabs were taken for
AH1N1 detection with PCR; results showed that positive
cases had significantly lower mean leucocyte counts, and
the association remained in the multivariate logistic regres-
sion analysis when the lymphocyte count was used [45].
However, it is worth noting that purulent rhinorrhea could
also result from a superimposed bacterial respiratory
infection [6].
Similarly, the symptomatology associated with lower
respiratory tract infections and its severity (e.g. cyanosis,
dyspnea and tachypnea) was also related to protective
odds. This finding might have to do with the time period
between the onset of the symptoms and the visit to the
health unit, as an indicator of the progression of the infec-
tion. However, no differences were seen in the mean num-
ber of days elapsed from the reported start of the
symptoms to the health visit (~3 days) between those who
had and did not have these symptoms (p > 0.05).
Very few clinical features might be relatively specific to
flu viral infections [27,46,47], such as the presence of clear
rhinorrhea that relates to the hemmagglutinin inhibiting
effect on the surface glycoproteins that protect the respira-
tory tract cilia [4]. Respiratory diseases caused by influenza
and parainfluenza viruses, adenoviruses or syncytial re-
spiratory virus usually produce similar unspecific clinical
symptomatology, characterized by fever, chills, malaise,
headache, myalgia or cough [48]. In fact, a recent review of
multivariate models devised to clinically diagnose influenza
reported that only the combination of fever, cough and
acute onset has a modest accuracy [49].
Compared with confirmed cases of seasonal influenza in
SLP during the same period, those with AH1N1 infection
aged ≥15 years showed significantly (p < 0.05) higher pro-
portions of cough, clear rhinorrhea, nasal congestion, sore
throat, malaise, chills, and myalgia (ranging from 8.3 to
16.4% higher), but had lower proportion of dyspnea
(5.3% less); however, among those aged 0–14 years, the
proportions were significantly higher only for cough (8.3%)
and clear rhinorrhea (8.7%) [26].
For the AH1N1 influenza virus infection, various studies
have not been able to identify symptoms that could predict
the presence of AH1N1 infection using various designs and
analytical procedures [50-52]. However, others have identi-
fied signs and symptoms associated to positive status. A
retrospective study with 117 adult cases and 236 matched
controls presenting with respiratory symptoms to hospital
emergency departments in Toronto, Canada, showed
higher associations for AH1N1 when various combinations
of signs, symptoms and laboratory indicators were used,
though only age, cough and fever remained associated in
the multivariate analyses [53]. Another study with military
personnel who visited primary health care clinics for febrile
respiratory illness (i.e. fever, cough and sore throat) com-
pared the signs and symptoms between those with positive
and negative AH1N1 influenza virus using real-time PCR.
Of the 2858 subjects recruited 821 were influenza cases, of
which 434 were 2009 pandemic influenza AH1N1. The
comparison of clinical features using multivariate logistic
regression showed that sore throat, photophobia, injected
pharynx and nausea/vomiting were negatively associated,
while running nose, chills, fever and eye symptoms were
positively related [54].
Conclusion
This study estimated the frequency and progression on the
AH1N1 influenza infection in symptomatic individuals,
and was able to identify various associated clinical features
that revealed the age specificity of several of them, indicat-
ing the importance of this factor when establishing the pre-
sumptive clinical diagnosis.
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